Similar studies for GEO DataSets (Select 5393) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO DataSets

Items: 3

Select item 53931.

Bipolar disorder and response to lithium: blood

Analysis of peripheral blood from patients with bipolar disorder before and 1 month after lithium treatment. Response of patients to lithium assessed after 6 months. Results identify a gene expression signature for the response to lithium treatment in patients with bipolar disorder.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 2 agent, 60 individual, 2 other, 2 time sets

Platform:: GPL10558
Series:: GSE45484
120 Samples

Download data

DataSet

Accession:: GDS5393

ID:: 5393

Select item 2000454842.

Gene-expression differences in peripheral blood between lithium responders and non-responders in the “Lithium Treatment -Moderate dose Use Study” (LiTMUS)

(Submitter supplied) Analysis of gene-expression changes in treatment responders vs non-responders to two different treatments among subjectrs participating in LiTMUS. Results provide information on pathways that may be involved in the clinical response to Lithium in patients with bipolar disorder.

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5393
Platform:: GPL10558
120 Samples

Download data: TXT

Series

Accession:: GSE45484

ID:: 200045484

Select item 2000083503.

mRNA expression profile in peripheral blood cells of RA patients following treatment with an anti-TNFa mAb, infliximab

(Submitter supplied) Objectives: We monitored the mRNA expression profiles of peripheral blood cells during treatment with a tumor necrosis factor-a inhibitor, infliximab, in patients with rheumatoid arthritis (RA). Using a DNA microarray analysis, we demonstrated a unique set of genes, with distinct baseline and post-treatment changes in expression between responders and non-responders to infliximab treatment.Methods: Using a customized low-density cDNA microarray and a reliable data collection system, we monitored the mRNA expression profiles of whole blood cells from 18 RA patients before and after the infusion of infliximab for up to 22 weeks. more...